Published On: 11/20/2018
TARGET PharmaSolutions to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead Sciences
CHAPEL HILL, NC – November 20, 2018 /PR NEWSWIRE/ – TARGET PharmaSolutions, Inc., a company focused on real world evidence, is pleased to announce that it has entered into a strategic partnership with Gilead Sciences for TARGET-NASH and TARGET-HBV. Gilead is the sixth partner in TARGET-NASH, joining Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Intercept and Novartis, and the first partner to join TARGET-Hepatitis B.
TARGET-NASH is a robust, meticulously-documented, longitudinal observational study that evaluates adult and pediatric patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). TARGET-NASH has enrolled over 4,250 patients to date and will enroll up to 15,000 patients in total over the coming years. TARGET-NASH is led by an academic steering committee chaired by Drs. Arun Sanyal, MD (Virginia Commonwealth University); Ken Cusi, MD (University of Florida), and Brent Tetri (Saint Louis University).
The academic steering committee co-chair, Dr. Arun Sanyal, MD stated “TARGET-NASH is critical for the scientific and regulatory community as we prepare for the plethora of new agents for the treatment of NASH. In the immediate term, it will give us a critical understanding of NASH diagnosis and management in the real world across multiple populations. In the longer term, it is the perfect platform to have a deep understanding of the safety and effectiveness of these new agents across populations not included or underrepresented in Phase 3 clinical trials.”
TARGET-HBV is an observational study that is evaluating patients with Hepatitis B. TARGET-HBV recently started enrolling patients and plans to enroll up to 5,000 patients across a diverse network of sites to advance our understanding of Hepatitis B.
Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions, stated “We are very excited to have Gilead join TARGET-NASH and TARGET-HBV. It is a privilege to partner with a company so focused on advancing the understanding of Liver Diseases.”
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
Contact:
Kayla Slake
Marketing Manager
984.234.0268 ext 205
More News
-
08/25/2022
New Approaches for Developing Real-World Evidence Presented by Target RWE at the 2022 International Conference on Pharmacoepidemiology (ICPE) -
08/24/2022
Durham-Based Target RWE Grows Data Abstraction, Curation Capabilities with Latest Acquisition -
08/23/2022
Target RWE New Brand, Research, and Advanced Real World Evidence Analytics Showcased at International Conference on Pharmacoepidemiology (ICPE) 2022 -
07/20/2022
Real-World Data Finds High Prevalence of Pruritus (Itching) and Fatigue, Low Levels of Treatment in Primary Biliary Cholangitis Population -
06/24/2022
Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022